Lance Waldmeier
Family · Vinton, LANPI 1750386140
Payments from drug & device makers
Across 167 payments — averaging $27.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$971
- Boehringer Ingelheim$467
- Merck$232
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$185
- Pfizer$169
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,523100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $1,072 |
| AstraZeneca | 22 | $971 |
| Boehringer Ingelheim | 7 | $467 |
| Merck | 3 | $232 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $185 |
| Pfizer | 9 | $169 |
| Lilly USA, LLC | 10 | $169 |
| Bayer | 3 | $151 |
| Astellas Pharma US Inc | 8 | $136 |
| Abbott | 2 | $132 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $124 |
| Cardiovascular Systems Inc. | 1 | $121 |
| Esperion Therapeutics, Inc. | 6 | $90 |
| Novo Nordisk | 5 | $87 |
| Gilead | 5 | $82 |
| Axsome Therapeutics, Inc. | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $54 |
| Supernus Pharmaceuticals, Inc. | 2 | $44 |
| Novartis | 2 | $38 |
| Ardelyx, Inc. | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| GSK | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Corium, LLC | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,523 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 86 | $108,028 |
| MounjaroTirzepatide | 77 | $100,878 |
| EliquisApixaban | 98 | $80,620 |
| JardianceEmpagliflozin | 85 | $79,663 |
| FarxigaDapagliflozin Propanediol | 51 | $57,210 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $38,962 |
| XareltoRivaroxaban | 31 | $31,185 |
| LinzessLinaclotide | 42 | $29,422 |
| MyrbetriqMirabegron | 23 | $29,126 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $26,364 |
| Xigduo XrDapaglifloz Propaned/Metformin | 28 | $22,013 |
| OzempicSemaglutide | 17 | $21,880 |
| Repatha SureclickEvolocumab | 18 | $18,016 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $17,111 |
| JanuviaSitagliptin Phosphate | 20 | $16,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $169 | $208,906163 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $971 | $105,567119 claims |
| Boehringer IngelheimJardiance, Tradjenta | $467 | $90,27098 claims |
| PfizerEliquis | $169 | $80,62098 claims |
| MerckJanuvia, Belsomra | $232 | $29,77951 claims |
| AbbVieLinzess | $1,072 | $29,42242 claims |
| Astellas Pharma US IncMyrbetriq | $136 | $29,12623 claims |
| Novo NordiskOzempic | $87 | $21,88017 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $15 | $20,57930 claims |
| NovartisEntresto | $38 | $13,27711 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $15 | $9,48814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.
Other family in Vinton
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.